Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

EudraCT

- PMLiVE

BriaCell advances personalised skin cancer immunotherapy vaccine candidate

Around 112,000 new cases of skin cancer will be diagnosed in the US in 2026

- PMLiVE

MSD and Moderna announce potential new vaccine for melanoma

The mRNA-based therapy, used with Keytruda, is designed specifically for each patient

- PMLiVE

Cases of skin cancer set to reach 263,000 in 2035 according to new report

The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

- PMLiVE

BioNTech announces £1bn UK investment to boost regional R&D presence

The UK government has also agreed to award the company a grant of up to £129m

- PMLiVE

NHS programme to give melanoma patients fast-track access to skin cancer vaccine

The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

- PMLiVE

British Skin Foundation receives £10,000 donation from Circle Health Group

The healthcare provider’s previous donation is supporting research into early melanoma detection

- PMLiVE

Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

The updated vaccine was shown to generate an improved response against currently circulating variants

- PMLiVE

Merck shares positive ten-year results for Keytruda in advanced melanoma

More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links